Texas Permanent School Fund grew its position in shares of NuVasive, Inc. (NASDAQ:NUVA) by 4.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 35,060 shares of the medical device company’s stock after buying an additional 1,410 shares during the quarter. Texas Permanent School Fund’s holdings in NuVasive were worth $1,991,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently bought and sold shares of NUVA. Virtu Financial LLC lifted its position in shares of NuVasive by 10.6% during the 4th quarter. Virtu Financial LLC now owns 4,860 shares of the medical device company’s stock worth $241,000 after buying an additional 464 shares in the last quarter. Bank of Montreal Can lifted its position in shares of NuVasive by 46.6% during the 4th quarter. Bank of Montreal Can now owns 7,976 shares of the medical device company’s stock worth $395,000 after buying an additional 2,535 shares in the last quarter. First Quadrant L P CA bought a new position in shares of NuVasive during the 4th quarter worth approximately $123,000. NJ State Employees Deferred Compensation Plan bought a new position in shares of NuVasive during the 4th quarter worth approximately $446,000. Finally, Fisher Asset Management LLC lifted its position in shares of NuVasive by 1.2% during the 4th quarter. Fisher Asset Management LLC now owns 1,272,638 shares of the medical device company’s stock worth $63,072,000 after buying an additional 15,359 shares in the last quarter.
NUVA has been the topic of a number of research reports. Needham & Company LLC cut shares of NuVasive from a “buy” rating to a “hold” rating in a report on Friday, February 8th. Jefferies Financial Group cut shares of NuVasive from a “buy” rating to a “hold” rating and set a $60.00 price target on the stock. in a report on Tuesday, February 12th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $50.00 price target on shares of NuVasive in a report on Monday, February 11th. BidaskClub raised shares of NuVasive from a “sell” rating to a “hold” rating in a report on Thursday, April 25th. Finally, Zacks Investment Research cut shares of NuVasive from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the company. NuVasive has an average rating of “Hold” and a consensus target price of $67.43.
NuVasive (NASDAQ:NUVA) last issued its earnings results on Wednesday, May 1st. The medical device company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.12. NuVasive had a net margin of 4.39% and a return on equity of 15.16%. The business had revenue of $274.78 million for the quarter, compared to analysts’ expectations of $269.22 million. During the same quarter in the previous year, the firm posted $0.39 EPS. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. Equities research analysts anticipate that NuVasive, Inc. will post 2.28 EPS for the current year.
In other news, President Matthew Link sold 10,100 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $62.00, for a total transaction of $626,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.97% of the company’s stock.
NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Article: Swap
Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.